NextCure, Inc.
Price Action
Technical Summary
CONSOLIDATINGNextCure, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 51), indicating performance broadly in line with the market. Earnings growth of 60% provides fundamental context to the price action. Investors should exercise caution due to high volatility (108% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.65 | -4.39% | BELOW |
| 50 SMA | $11.20 | -9.08% | BELOW |
| 100 SMA | $11.82 | -13.89% | BELOW |
| 150 SMA | $11.22 | -9.23% | BELOW |
| 200 SMA | $9.73 | +4.61% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NXTC in an uptrend right now?
NXTC has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NXTC overbought or oversold?
NXTC's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is NXTC outperforming the market?
NXTC has a Relative Strength (RS) Rating of 51 out of 99. NXTC is performing about average compared to the market.
Where is NXTC in its 52-week range?
NXTC is trading at $10.18, which is 65% of its 52-week high ($15.74) and 52% above its 52-week low ($4.09).
How volatile is NXTC?
NXTC has a Beta of 0.61 and 52-week volatility of 108%. It's less volatile than the S&P 500 - generally more stable.